Promedior

56 articles with Promedior

• Promedior Announces Completion of Acquisition by Roche

  2/13/2020

  LEXINGTON, Mass. , Feb. 13, 2020 /PRNewswire/ -- Promedior, Inc. today announced the successful completion of its previously announced sale to Roche (SIX: RO, ROG; OTCQX: RHHBY). With this acquisition, Roche obtained full rights to Promedior's entire portfolio of molecules for serious fibrotic diseases, notably PRM-151. Under the terms of the merger agreement, Roche made an up

• 

  M&A for 2019 was Big; Will 2020 Be Even Bigger?

  1/13/2020

  Consulting firm EY released its annual report on mergers and acquisitions (M&A) to coincide with the JP Morgan Healthcare conference this week. For 2019, EY indicates there were $357 billion in life science deals, an “all-time record,” surpassing the previous high in 2014.

• Promedior Enters Into Definitive Merger Agreement To Be Acquired By Roche

  11/15/2019

  Promedior, Inc., today announced that it has entered into a definitive merger agreement for Roche (SIX: RO, ROG; OTCQX: RHHBY) to acquire Promedior

• 

  Roche to Acquire Fibrosis-Focused Promedior for Up to $1.4 Billion

  11/15/2019

  Under the terms of the agreement, Roche will make an upfront cash payment of $390 million, plus additional contingent payments of up to $1 billion based on the achievement of certain predetermined development, regulatory and commercial milestones.

• Promedior Presents Positive Data from a Phase 2 Study of PRM-151 in Myelofibrosis Patients Failed/Ineligible for Ruxolitinib at the 24th European Hematology Association Annual Congress

  6/17/2019

  Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, announced  positive safety and efficacy data from a Phase 2 study of PRM-151 in myelofibrosis (MF) patients that either failed (76%) or were ineligible for Ruxolitinib.

• Promedior Announces Positive Long-term Safety and Efficacy Data from Open Label Extension Study of PRM-151 in Idiopathic Pulmonary Fibrosis

  5/20/2019

  Promedior, Inc today announced that positive safety and efficacy data from the Company's open-label extension study of PRM-151 in patients with Idiopathic Pulmonary Fibrosis (IPF) were simultaneously published in The Lancet Respiratory Medicine and presented at the American Thoracic Society 2019 International Conference

• Promedior Received Breakthrough Therapy Designation from FDA for PRM-151 in Idiopathic Pulmonary Fibrosis

  3/26/2019

  Promedior, Inc. announced that PRM-151, a novel investigational anti-fibrotic immunomodulator, has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration for Idiopathic Pulmonary Fibrosis.

• Promedior Announces Pivotal Path for PRM-151 in Idiopathic Pulmonary Fibrosis Following Positive End-of-Phase 2 Meeting with FDA

  1/4/2019

  Promedior, Inc., announced that it has completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to discuss the study of PRM-151, a novel investigational anti-fibrotic immunomodulator, in patients with Idiopathic Pulmonary Fibrosis (IPF)

• Exec Who Orchestrated Promedior's $1.25 Billion Buyout Deal From Bristol-Myers Squibb To Helm Proclara

  4/26/2017

• Promedior Announces Completion Of Patient Enrollment Milestones In Phase 2 Clinical Studies Of PRM-151 In Both Idiopathic Pulmonary Fibrosis And Myelofibrosis

  12/2/2016

• Promedior Presents Positive Phase II Data For PRM-151 In Myelofibrosis At American Society of Hematology Annual Meeting

  12/10/2015

• Promedior Announces Initiation Of A Phase II Clinical Study Of PRM-151 In Idiopathic Pulmonary Fibrosis (IPF)

  9/8/2015

• Bristol-Myers Squibb Bags Rights to Buy Promedior in Deal Worth $1.25 Billion

  9/1/2015

• Promedior Presents Additional Positive Phase 2 Data For PRM-151 In Myelofibrosis At EHA Annual Meeting

  6/12/2015

• Promedior Announces Presentation Of Additional Positive Phase II Data On PRM-151 In Myelofibrosis At The Upcoming Congress Of The European Hematology Association

  6/4/2015

• Promedior Presents Positive Phase 2 Data For PRM-151 In Myelofibrosis At American Society of Hematology Annual Meeting

  12/9/2014

• Promedior Receives Fast Track Designation For PRM-151 For The Treatment Of Myelofibrosis

  11/3/2014

• Promedior Announces Presentation Of Retrospective Quantitative Imaging Analysis Of Phase 1b Data In Idiopathic Pulmonary Fibrosis

  9/22/2014

• Promedior Receives U.S. Orphan Drug Designation For PRM-151 For The Treatment Of Myelofibrosis

  9/2/2014

• Promedior Receives U.S. Orphan Drug Designation For PRM-151 For Fhe Treatment Of Myelofibrosis

  9/2/2014